What could be the cause of hemoglobin drop in a patient with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) who developed a stroke while on warfarin with an INR of 1.6?

Hemoglobin Drop in SLE/APS Patient on Subtherapeutic Warfarin

The most likely cause of hemoglobin drop in this patient is bleeding—either occult gastrointestinal hemorrhage or another site—precipitated by inadequate anticoagulation (INR 1.6) that failed to prevent thrombotic stroke, combined with the inherent bleeding risk from warfarin itself and potential hematologic manifestations of SLE.

Primary Diagnostic Considerations

1. Bleeding (Most Likely)

The patient is on warfarin with an INR of 1.6, which is subtherapeutic for APS (target INR 2.0-3.0) 1, 2. This creates a paradoxical situation:

• Subtherapeutic anticoagulation allowed thrombotic stroke to occur
• Concurrent warfarin exposure still carries bleeding risk, particularly with:
  • Gastrointestinal bleeding (most common site)
  • Intracranial hemorrhage (especially post-stroke)
  • Genitourinary bleeding
  • Retroperitoneal bleeding

Critical Action: Immediately check stool for occult blood, perform CT head to exclude hemorrhagic transformation of ischemic stroke, examine urine for hematuria, and assess for any signs of bleeding at other sites.

2. Autoimmune Hemolytic Anemia (AIHA)

SLE commonly causes AIHA 3, 4, 5. This is a disease-related cause independent of anticoagulation:

• Check direct Coombs test (direct antiglobulin test)
• Review peripheral smear for spherocytes, schistocytes
• Check reticulocyte count (elevated in hemolysis)
• Assess LDH, indirect bilirubin, haptoglobin

AIHA in SLE requires treatment with moderate/high-dose corticosteroids, potentially with immunosuppressants (azathioprine, MMF, or cyclosporine) 3. Recent case reports confirm AIHA can coexist with APS and stroke 6.

3. Anemia of Chronic Disease

Common in SLE patients (equally distributed across SLE and APS populations at ~32-36%) 7:

• Check ferritin (typically elevated >100 in inflammatory states)
• IL-6 and hsCRP levels correlate with ferritin in APS/SLE 7
• This is typically gradual, not acute drop

4. Iron Deficiency Anemia

Most common in primary APS (61.9% IDA, 64.3% iron deficiency without anemia) 7:

• Ferritin is the independent predictor of IDA 7
• Often from chronic occult GI bleeding
• Check ferritin, TIBC, serum iron

Critical Management Algorithm

Immediate Steps (First 24 Hours)

1. Assess for active bleeding:

   • Stool guaiac/fecal occult blood
   • CT head (hemorrhagic transformation)
   • Urinalysis
   • Physical exam for ecchymoses, petechiae

2. Laboratory workup:

   • CBC with differential, reticulocyte count
   • Direct Coombs test
   • Peripheral blood smear
   • LDH, indirect bilirubin, haptoglobin
   • Ferritin, iron studies
   • Type and screen

3. Evaluate stroke type:

   • Confirm ischemic vs hemorrhagic on imaging
   • If hemorrhagic transformation: HOLD warfarin, consider reversal with vitamin K ± FFP/PCC

Anticoagulation Management Dilemma

This patient faces competing risks:

• Stroke occurred at INR 1.6 (subtherapeutic for APS)
• APS with stroke requires INR 2.0-3.0 1, 2
• Hemoglobin drop suggests bleeding risk

Decision Algorithm:

IF bleeding source identified AND active:

• Hold warfarin temporarily
• Address bleeding source (endoscopy, embolization, etc.)
• Consider IVC filter if extensive DVT risk
• Resume anticoagulation only after hemostasis achieved 8

IF no active bleeding found:

• Cautiously increase warfarin to achieve INR 2.0-3.0 1
• Monitor hemoglobin daily
• Consider chromogenic factor X monitoring if lupus anticoagulant interferes with INR reliability 9, 10

IF AIHA confirmed:

• Initiate high-dose corticosteroids (methylprednisolone 1g IV × 3 days, then oral prednisone) 3
• Add immunosuppressant (azathioprine, MMF, or cyclosporine) 3
• Continue anticoagulation for APS/stroke

Common Pitfalls

1. Assuming INR 1.6 is "safe": This level failed to prevent stroke and is inadequate for APS 1

2. Lupus anticoagulant interference: LA can falsely elevate INR, making warfarin monitoring unreliable 9, 10. Consider chromogenic factor X assay (target 20-40% activity) 9

3. Overlooking hemorrhagic transformation: Post-stroke patients on anticoagulation must have repeat imaging if hemoglobin drops

4. Missing AIHA: Direct Coombs test is essential in any SLE patient with anemia 3, 4

5. Delaying anticoagulation indefinitely: In triple-positive APS with thrombosis, prolonged anticoagulation interruption risks recurrent thrombosis 8. Balance must be individualized with hematology input

Specific to This Case

The INR of 1.6 is critically important: This patient had inadequate anticoagulation for APS, which directly contributed to stroke 1, 2. The hemoglobin drop could represent:

• Bleeding from warfarin (even at subtherapeutic levels)
• AIHA from active SLE
• Combination of both

Next steps must include: Urgent evaluation for bleeding sources, hemolysis workup, and careful warfarin dose adjustment to achieve INR 2.0-3.0 once bleeding is excluded or controlled 1, 2.